Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1991-4-17
|
pubmed:abstractText |
A series of renin inhibitors containing lactam-bridged P1-P1' dipeptide mimetics based on the ACHPA (4(S)-amino-5-cyclohexyl-3(S)-hydroxypentanoic acid) design was studied. The inhibitors were obtained by aldol addition of various lactams with N alpha-Boc-L-cyclohexylalaninal, followed by Boc group removal and acylation with Boc-Phe-His. The aldol diastereomer having the S configuration at the two newly generated stereogenic centers gave optimal enzyme inhibition. Potency was further enhanced in the gamma-lactam ring series by substitution with small hydrophobic groups to mimic the P1' side chain of the renin substrate. Thus, 2(S)-[(Boc-L-phenylalanyl-L-histidyl)amino]-3-cyclohexyl-1(S)-hydroxyl-1 - (1,5,5-trimethyl-2-oxopyrrolidin-3(S)-yl)propane (34) has an IC50 of 1.3 nM in the human plasma renin assay. A variety of substituents on the lactam nitrogen are tolerated and can be used to vary the physical properties of the inhibitor. By using a model of the human renin active site, the conformation of 34 in the enzyme-inhibitor complex is proposed. This modeled conformation is very similar to the solid-state conformation of 2(S)-[(Boc-L-phenylalanyl-L-histidyl)amino]-3-cyclohexyl-1(S)-hydroxyl- 1-(1-methyl-2-oxopyrrolidin-3(S)-yl)propane (36), the structure of which was determined by single-crystal X-ray diffraction analysis. The most potent ACH-PA-lactam renin inhibitors show good selectivity when assayed against other types of aspartic proteinases. By varying the lactam ring substituents, potent and selective inhibitors of cathepsin D and cathepsin E can be obtained.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0022-2623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
887-900
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:2002469-Animals,
pubmed-meshheading:2002469-Binding Sites,
pubmed-meshheading:2002469-Chemical Phenomena,
pubmed-meshheading:2002469-Chemistry,
pubmed-meshheading:2002469-Dipeptides,
pubmed-meshheading:2002469-Female,
pubmed-meshheading:2002469-Humans,
pubmed-meshheading:2002469-Kinetics,
pubmed-meshheading:2002469-Macaca mulatta,
pubmed-meshheading:2002469-Male,
pubmed-meshheading:2002469-Models, Molecular,
pubmed-meshheading:2002469-Molecular Conformation,
pubmed-meshheading:2002469-Molecular Structure,
pubmed-meshheading:2002469-Oligopeptides,
pubmed-meshheading:2002469-Renin,
pubmed-meshheading:2002469-Structure-Activity Relationship,
pubmed-meshheading:2002469-X-Ray Diffraction
|
pubmed:year |
1991
|
pubmed:articleTitle |
Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.
|
pubmed:affiliation |
Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania 19486.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|